Physician profile
Kumud Tripathy
NPI 1811949407
$1,849.39
in general payments reported to CMS, 2019-2025
33 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $540 · 2020: $18.11 · 2021: $369 · 2022: $543 · 2023: $294 · 2024: $84.96.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $379.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $379.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $309.47 | 2019-2022 | |
| Janssen Biotech, INC. | $258.19 | 2019-2023 | Darzalex, Tecvayli, Erleada |
| Myriad Genetic Laboratories, INC. | $128.82 | 2021 | |
| Incyte Corporation | $125.00 | 2019 | |
| Jazz Pharmaceuticals INC. | $121.14 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $88.01 | 2019-2023 | Keytruda |
| Tempus Ai, INC | $84.96 | 2024 | Xt Cdx |
| Celgene Corporation | $72.93 | 2021-2023 | Pomalyst |
| Lilly USA, LLC | $61.83 | 2019-2023 | Verzenio, Retevmo, Jaypirca |
| Astrazeneca Pharmaceuticals LP | $50.57 | 2022-2023 | |
| Regeneron Healthcare Solutions, INC. | $44.89 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $32.75 | 2022 | |
| Gilead Sciences, INC. | $31.91 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.50 | 2021-2022 | |
| Ipsen Biopharmaceuticals, INC | $30.28 | 2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Deciphera Pharmaceuticals INC. | $30.00 | 2022 | |
| Organon LLC | $28.89 | 2023 | Ontruzant |
| Spectrum Pharmaceuticals INC. | $27.72 | 2023 | Rolvedon |
| Tersera Therapeutics LLC | $25.93 | 2021 | |
| Dendreon Pharmaceuticals LLC | $24.77 | 2022 | |
| Adaptive Biotechnologies Corporation | $24.54 | 2022 | |
| Daiichi Sankyo INC. | $22.85 | 2023 | Injectafer |
| Tesaro, INC. | $22.62 | 2019 | |
| Eisai INC. | $21.55 | 2019 | |
| Seagen INC. | $21.37 | 2023 | Adcetris |
| Genentech USA, INC. | $21.36 | 2023 | Rituxan Hycela, Polivy, Lunsumio |
| Glaxosmithkline, LLC. | $18.83 | 2021 | |
| Genzyme Corporation | $18.61 | 2019 | |
| Pfizer INC. | $17.63 | 2021 | |
| Exelixis INC. | $14.51 | 2021 | |
| Tactile Systems Technology INC | $13.77 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $11.99 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $11.20 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kumud Tripathy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.